Paclitaxel and Trastuzumab Treatment in Early-Stage HER2-Positive Breast Cancer
In this article
Early-stage HER2-positive breast cancer is among the areas of oncology practice that have evolved most over the past 20 years. After the HER2 receptor was identified in the 1980s, this tumor type was recognized as biologically more aggressive; however, the development of HER2-targeted drugs such as trastuzumab, pertuzumab, and T-DM1 and their combination with chemotherapy have dramatically reduced recurrence risk in early-stage HER2-positive patients today. Particularly in the subgroup with tumors measuring 1–2 cm, pT1cN0M0 , treatment decisions rely not only on surgical and pathological findings, but also on biological markers, general condition, hormone receptor positivity, and international guideline recommendations.
For a patient whose pathological stage after breast-conserving surgery is pT1cN0M0 and who is ER/PR-positive and HER2-positive , this article discusses adjuvant treatment in light of scientific data, phase III clinical trials, ESMO–NCCN 2024/2025 guidelines, and current literature. A typical treatment sequence is:
- 12 weeks of weekly paclitaxel + trastuzumab (APT protocol)
- Then continue trastuzumab for a total duration of 1 year
- Radiotherapy (mandatory after breast-conserving surgery)
- 5–10 years of hormone therapy (tamoxifen or an aromatase inhibitor)
HER2-positive tumors in the pT1c subgroup (1–2 cm) carry a higher recurrence risk than T1a (≤0.5 cm) and T1b (0.5–1 cm) tumors. This subgroup is therefore considered to require adjuvant anti-HER2 therapy. ER/PR positivity also creates a dual-marker tumor biology (HER2+/HR+); interactions between HER2 signaling and estrogen receptor pathways are important in planning treatment for this form.
This article aims to explain, through extensive clinical data and molecular mechanisms, why a HER2-positive patient with postoperative pathology of pT1cN0M0 receives 12 weeks of paclitaxel + trastuzumab, why trastuzumab continues for 1 year, why radiotherapy is mandatory, and why hormone therapy is a step that cannot be deferred.
The Clinical Importance of Pathological Staging and Prognostic Factors
Pathological staging is the foundation of adjuvant treatment decisions in early-stage HER2-positive breast cancer. pT1cN0M0 tumors measure 1–2 cm and have no axillary lymph node metastases. This group has a higher recurrence risk than T1a-b N0 patients.
1. Biological Risk in T1c Tumors
- HER2 positivity → high proliferation rate
- Usually elevated Ki-67 (≥20–30%)
- A more aggressive growth pattern
- ER/PR positivity → dual pathway activation
In the T1c subgroup, metastatic recurrence risk without treatment can reach 20–25%. After trastuzumab, this has fallen to 3–5% — demonstrating the effectiveness of adjuvant treatments.
2. Grade
- HER2-positive tumors are mostly Grade 3.
- Without treatment, Grade 3 tumors have a substantially increased recurrence risk.
3. Ki-67
A high Ki-67 proliferation index is a prognostic indicator in HER2-positive tumors. Above 30%, the recommendation for chemotherapy + anti-HER2 therapy is stronger.
4. Lymphovascular Invasion (LVI)
LVI significantly increases recurrence risk. In T1cN0M0 patients, LVI positivity is an additional criterion for a firmer recommendation of chemotherapy and trastuzumab.
5. Hormone Receptor Positivity
Although ER/PR positivity alone appears to be a better prognostic sign, tumor biology becomes more complex alongside HER2 positivity.
- HER2 → proliferation through MAPK and PI3K/Akt
- ER → hormonal proliferation and maintenance of gene expression
- Dual activation → more resistant tumor behavior
Both anti-HER2 therapy and hormone therapy are therefore mandatory in the HER2+/HR+ subtype.
The Scientific Basis of Adjuvant Treatment
In early-stage HER2-positive breast cancer, adjuvant treatment aims to eradicate microscopic residual disease and minimize both local and distant recurrence. Untreated HER2 positivity has an aggressive course, but modern anti-HER2 treatments can control this aggressive biology.
1. Why Is Treatment Mandatory in T1cN0 Patients?
While the risk–benefit balance in T1a and T1b HER2-positive tumors is assessed individually, T1c (1–2 cm) tumors are a definite indication for anti-HER2 therapy in international guidelines.
- NCCN 2024: T1c HER2+ → chemotherapy + trastuzumab firmly recommended
- ESMO 2023 and 2024: T1c → systemic treatment is mandatory
- ASCO: adjuvant anti-HER2 therapy is standard for T1c HER2-positive patients
This is because, in the T1c group:
- Metastatic spread risk is significant despite negative lymph nodes
- HER2-driven proliferative biology
- HER2 positivity defines a chemotherapy-sensitive subtype
2. Which Adjuvant Regimens Are Preferred?
Adjuvant treatment options for T1–T2, N0–N1 HER2-positive patients:
- A. APT Regimen: Weekly Paclitaxel + Trastuzumab (12 weeks)
- B. AC → TH (anthracycline-based)
- C. TCH (Docetaxel + Carboplatin + Trastuzumab)
However, for T1cN0M0 and similar low-to-intermediate-risk but HER2-positive patients, the best benefit–risk ratio is provided by the APT Regimen .
3. Why Is APT (Paclitaxel + Trastuzumab) Preferred?
- Lower toxicity
- Better cardiac safety profile
- Excellent survival outcomes extending to 10 years
- An ideal risk/benefit balance for N0 patients
The APT study is the main foundation of this approach.
The APT Regimen: Scientific Basis of Weekly Paclitaxel + Trastuzumab
The strongest scientific basis for giving 12 weeks of paclitaxel + trastuzumab (APT protocol) to a pT1cN0M0 HER2-positive, ER/PR-positive patient is the APT (Adjuvant Paclitaxel and Trastuzumab) study. It showed that a less intensive chemotherapy regimen could achieve high efficacy in "small but HER2-positive tumors with low nodal risk."
1. APT Study Design
- Single-arm phase II study
- Included patients: T1a–T1c, N0–N1(mic) HER2-positive invasive breast cancer
- Lymph node status: mostly N0
- Regimen:
- Weekly paclitaxel 80 mg/m² for 12 weeks
- Concurrent trastuzumab (loading + weekly or every 3 weeks)
- Total trastuzumab duration: 1 year
The APT study is considered a milestone for showing how much an anthracycline-free, relatively low-toxicity regimen can reduce long-term recurrence risk in small HER2-positive tumors.
2. APT Study Results
Long-term follow-up data (analyses extending to 7 and 10 years):
- 7-year invasive disease-free survival (iDFS) ≈ 93–95%
- Distant metastasis rates are extremely low (approximately 1–2%)
- Similarly low recurrence rates were maintained at 10-year follow-up.
Particularly in node-negative T1c tumors, more intensive regimens (AC-TH, TCH) achieve similarly good recurrence rates, while APT offers similar protection with less toxicity. Guidelines therefore highlight APT as a strong option for T1c patients with low nodal risk.
3. Toxicity Profile
In the APT study:
- Neuropathy: the rate of Grade 2–3 peripheral neuropathy is relatively low and reversible in most patients.
- Cardiac toxicity: symptomatic heart failure occurs in less than 1%.
- Myelosuppression: usually mild to moderate, better tolerated than intensive anthracycline regimens.
This toxicity profile makes APT attractive to clinicians, particularly for early-stage N0 patients with comorbidities or cardiac risk factors.
4. Why an Anthracycline-Free Regimen?
Although effective in HER2-positive patients, anthracyclines (doxorubicin, epirubicin):
- Increase cardiotoxicity risk.
- Slightly increase the risk of second malignancies (particularly leukemia/MDS).
- Have cumulative dose limitations.
For a biologically aggressive but low-tumor-burden group such as T1cN0M0, the combination of paclitaxel + trastuzumab provides similar efficacy without unnecessary toxicity, making it a more balanced choice than anthracycline-containing regimens.
5. APT in the ER/PR-Positive T1c HER2+ Subtype
In hormone receptor-positive HER2+ patients, systemic treatment is not limited to chemotherapy + trastuzumab; long-term hormone therapy follows. Thus:
- A short, well-tolerated chemotherapy regimen
- Suppression of microscopic HER2+ clones with 1 year of trastuzumab
- Subsequent control of residual hormone-sensitive cells with endocrine therapy
form a "stepwise approach." APT provides the first two components of this structure in a robust, controlled, tolerable way.
One Year of Trastuzumab: Historical Evidence, Dosing, and Cardiac Monitoring
In early-stage HER2-positive breast cancer, 1 year of adjuvant trastuzumab became standard through pooled results of several phase III trials. While APT demonstrated its combination with paclitaxel in small tumors, HERA, NSABP B-31, NCCTG N9831, and BCIRG-006 in larger and/or node-positive tumors showed that trastuzumab significantly reduced metastatic recurrence risk.
1. The HERA Study
- Patients were randomized after completing neoadjuvant/adjuvant chemotherapy.
- Disease-free survival was significantly better in the group receiving 1 year of trastuzumab.
- Long-term follow-up also showed that the benefit persisted.
2. NSABP B-31 and NCCTG N9831
These two studies showed that adding a taxane + trastuzumab to anthracycline-based chemotherapy (AC):
- Significantly improved disease-free survival,
- Reduced distant metastases,
- Provided an overall survival benefit.
Patients in these studies were closely monitored for cardiac toxicity, and trastuzumab was temporarily withheld in those with an EF decline.
3. BCIRG-006
This study compared AC-TH with anthracycline-free TCH (docetaxel + carboplatin + trastuzumab), showing similar efficacy with lower cardiotoxicity for TCH. This increased the value of anthracycline-free regimens in HER2 treatment.
4. Why 1 Year?
Different studies compared 6-month, 9-month, and 1-year trastuzumab regimens; meta-analyses showed:
- Although 6 months appeared noninferior in some subgroup analyses, it could consistently fall short of 1 year,
- 12 months became the "benchmark,"
- Longer treatment (2 years) provided no additional benefit.
The standard duration in current practice is therefore 1 yearin total.
5. Cardiac Monitoring
Trastuzumab causes cardiotoxicity through a different mechanism from anthracyclines, and it is often reversible. Nevertheless, recommendations include:
- Baseline echocardiography (EF measurement)
- EF monitoring every 3 months during treatment
- A treatment break if symptomatic heart failure or a substantial EF decline is detected.
This cardiac monitoring is standard even with anthracycline-free regimens such as APT, because trastuzumab's potential to stress cardiomyocytes through HER2 blockade has not been entirely eliminated.
Radiotherapy After Breast-Conserving Surgery
Adjuvant radiotherapy is standard for all patients undergoing breast-conserving surgery (lumpectomy), unless there is a serious contraindication. In a pT1cN0M0 HER2-positive, ER/PR-positive patient, radiotherapy:
- Significantly reduces local recurrence risk.
- Provides long-term local control.
- Is an integral part of the breast-conserving strategy.
1. Treatment Fields
- The entire breast tissue (whole breast irradiation)
- A tumor-bed boost if needed (particularly young age, high grade, close surgical margins, etc.)
2. Timing
Radiotherapy is generally given:
- After chemotherapy has been completed,
- Alongside ongoing trastuzumab.
Concurrent radiotherapy and trastuzumab are generally considered safe; EF monitoring is performed even more carefully for cardiotoxicity.
3. Hypofractionated Radiotherapy
Current guidelines accept hypofractionated radiotherapy (shorter duration, higher dose per fraction)as a standard option in suitable patients.
- For example, schedules completed in 15–16 fractions
- Have local control rates similar to conventional schedules.
- Offer advantages in patient convenience and logistics.
Endocrine Therapy: The Approach in an ER/PR-Positive, HER2-Positive T1cN0M0 Patient
In ER/PR-positive HER2-positive tumors, the final, long-term component of adjuvant treatment is hormone therapy. This aims to reduce late recurrence by suppressing hormone-dependent tumor subclones.
1. Premenopausal Patients
The main option in premenopausal patients is tamoxifen. However, an aromatase inhibitor with ovarian suppression (LHRH analogs) has also become an option in high-risk subgroups.
- Lower-risk premenopausal patient: 5 years of tamoxifen
- Higher-risk, young, intensively treated patient: 5 years of tamoxifen + ovarian suppression or 5 years of AI + ovarian suppression
2. Postmenopausal Patients
In postmenopausal patients:
- The first choice is generally an aromatase inhibitor (letrozole, anastrozole, exemestane)
- Total duration is individualized between 5–10 years.
3. Endocrine Response in the HER2-Positive, HR-Positive Subtype
In HER2+/HR+ tumors, endocrine response is somewhat more complex than in tumors that are only hormone receptor-positive. Active HER2 signaling can sometimes develop mechanisms of hormone therapy resistance. Therefore, in this subtype:
- Anti-HER2 therapy (trastuzumab) and endocrine therapy are both given.
- Long-term endocrine therapy plays an important role in reducing late recurrence.
4. Treatment Duration
Current guidelines recommend, according to the patient's risk profile:
- At least 5 years of endocrine therapy
- Extension to a total of 7–10 years in selected high-risk patients
as treatment options.
Follow-Up, Adverse Effect Management, and Long-Term Monitoring After Treatment
After a pT1cN0M0, ER/PR-positive, HER2-positive patient completes all adjuvant treatments (chemotherapy + 1 year of trastuzumab + radiotherapy + endocrine therapy), the focus shifts to lifelong follow-up and managing late effects.
1. Oncological Follow-Up
- First 2–3 years: examination every 3–6 months
- Subsequent years: check-ups 1–2 times a year
- Annual mammography (treated + opposite breast, depending on the surgical method)
2. Cardiac Follow-Up
Particularly in patients treated with trastuzumab and, if applicable, anthracyclines:
- Joint cardiology follow-up for those with low EF
- Echocardiography and assessment if significant symptoms develop (shortness of breath, edema, easy fatigability)
3. Endocrine Therapy Adverse Effects
- Tamoxifen: thromboembolism risk, endometrial thickening, vasomotor symptoms
- AI: osteoporosis, joint pain, lipid profile changes
Managing these adverse effects is critical to maintaining treatment adherence.
4. Psychosocial Support
Even in early-stage breast cancer, diagnosis and treatment can cause depression, anxiety, and adjustment difficulties. Therefore:
- Psycho-oncology support
- Patient support groups
- Counseling on nutrition, physical activity, and weight control
should be integral parts of treatment.
For a patient with a pathological stage after breast-conserving surgery of pT1cN0M0, ER/PR-positive and HER2-positive disease, 12 weeks of paclitaxel + trastuzumab (APT regimen), followed by trastuzumab to a total of 1 year, breast radiotherapy, and long-term endocrine therapy form a balanced adjuvant sequence with high efficacy and safety, based on current evidence.
APT showed that an anthracycline-free regimen with relatively manageable neuropathy can achieve exceptionally low recurrence rates in small HER2-positive tumors; studies such as HERA, NSABP B-31, N9831, and BCIRG-006 demonstrated that trastuzumab dramatically reduces recurrence risk in early-stage HER2-positive patients. Endocrine therapy added for ER/PR positivity plays a critical role, particularly in preventing late recurrence.
Thus, in pT1cN0M0 HER2+/HR+ early-stage breast cancer, this stepwise approach is a rational strategy aligned with international guidelines and aimed at maximizing long-term survival and quality of life.
References
- Tolaney SM, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT trial). N Engl J Med.
- Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (HERA trial). N Engl J Med.
- Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer (NSABP B-31, N9831). N Engl J Med.
- Slamon D, et al. Adjuvant trastuzumab in HER2-positive breast cancer (BCIRG-006). N Engl J Med.
- ESMO Clinical Practice Guidelines for Early Breast Cancer, 2023–2024.
- NCCN Guidelines, Breast Cancer, 2024.
- ASCO Clinical Practice Guidelines for HER2-positive Early Breast Cancer.
- Coates AS, et al. Tailoring therapies—improving the management of early breast cancer. St Gallen Consensus.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.